AU2016246722B2 - Anti-Flt-1 antibodies for treating duchenne muscular dystrophy - Google Patents

Anti-Flt-1 antibodies for treating duchenne muscular dystrophy Download PDF

Info

Publication number
AU2016246722B2
AU2016246722B2 AU2016246722A AU2016246722A AU2016246722B2 AU 2016246722 B2 AU2016246722 B2 AU 2016246722B2 AU 2016246722 A AU2016246722 A AU 2016246722A AU 2016246722 A AU2016246722 A AU 2016246722A AU 2016246722 B2 AU2016246722 B2 AU 2016246722B2
Authority
AU
Australia
Prior art keywords
seq
antibody
amino acid
acid sequence
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016246722A
Other languages
English (en)
Other versions
AU2016246722A1 (en
Inventor
Hans De Haard
Natalie De Jonge
Sofie Gabriels
Dennis KEEFE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2016246722A1 publication Critical patent/AU2016246722A1/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: SHIRE HUMAN GENETIC THERAPIES, INC.
Application granted granted Critical
Publication of AU2016246722B2 publication Critical patent/AU2016246722B2/en
Priority to AU2022200466A priority Critical patent/AU2022200466B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2016246722A 2015-04-07 2016-04-07 Anti-Flt-1 antibodies for treating duchenne muscular dystrophy Active AU2016246722B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022200466A AU2022200466B2 (en) 2015-04-07 2022-01-25 Anti-Flt-1 antibodies for treating duchenne muscular dystrophy

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562144251P 2015-04-07 2015-04-07
US62/144,251 2015-04-07
US201662307645P 2016-03-14 2016-03-14
US62/307,645 2016-03-14
PCT/US2016/026352 WO2016164528A1 (en) 2015-04-07 2016-04-07 Anti-flt-1 antibodies for treating duchenne muscular dystrophy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022200466A Division AU2022200466B2 (en) 2015-04-07 2022-01-25 Anti-Flt-1 antibodies for treating duchenne muscular dystrophy

Publications (2)

Publication Number Publication Date
AU2016246722A1 AU2016246722A1 (en) 2017-10-26
AU2016246722B2 true AU2016246722B2 (en) 2021-10-28

Family

ID=55754471

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016246722A Active AU2016246722B2 (en) 2015-04-07 2016-04-07 Anti-Flt-1 antibodies for treating duchenne muscular dystrophy
AU2022200466A Active AU2022200466B2 (en) 2015-04-07 2022-01-25 Anti-Flt-1 antibodies for treating duchenne muscular dystrophy

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022200466A Active AU2022200466B2 (en) 2015-04-07 2022-01-25 Anti-Flt-1 antibodies for treating duchenne muscular dystrophy

Country Status (10)

Country Link
US (3) US10787515B2 (enExample)
EP (2) EP3280734B1 (enExample)
JP (3) JP6993880B2 (enExample)
CN (3) CN114539408B (enExample)
AU (2) AU2016246722B2 (enExample)
ES (1) ES2910783T3 (enExample)
MA (1) MA41899A (enExample)
MX (1) MX2017012828A (enExample)
PL (1) PL3280734T3 (enExample)
WO (1) WO2016164528A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41899A (fr) 2015-04-07 2018-02-13 Shire Human Genetic Therapies Anticorps anti-flt-1 pour traiter la dystrophie musculaire de duchenne
JP2022513693A (ja) * 2018-11-29 2022-02-09 ハーバー・バイオメド・セラピューティクス・リミテッド 抗ｐｄ－ｌ１抗体製剤
BR112022002028A2 (pt) * 2019-08-02 2022-04-12 Cttq Akeso Shanghai Biomed Tech Co Ltd Anticorpo anti-pd-1 e uso farmacêutico do mesmo
CN114230666B (zh) * 2021-12-20 2022-09-02 南京诺唯赞生物科技股份有限公司 一种t7 rna聚合酶的单克隆抗体及其制备方法
WO2026072909A2 (en) * 2024-09-27 2026-04-02 Amgen Inc. Flt1 binding proteins and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014117160A1 (en) * 2013-01-28 2014-07-31 Shire Human Genetic Therapies, Inc. Anti-flt-1 antibodies in treating duchenne muscular dystrophy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8287864B2 (en) * 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
EP2377555A3 (en) 2004-11-18 2011-11-23 Imclone LLC Antibodies against vascular endothelial growth factor receptor-1
CA2746395C (en) 2008-12-10 2019-07-09 Ablynx N.V. Polypeptides comprising amino acid sequences directed against tie 2 for the treatment of diseases and disorders related to angiogenesis
CA2826563C (en) * 2011-02-07 2020-10-20 Paul Kussie Methods and systems for treating eclampsia and pre-eclampsia
TW201517916A (zh) * 2013-03-15 2015-05-16 Lilly Co Eli Ｖｅｇｆｒ１抗體之治療用途
MA41899A (fr) 2015-04-07 2018-02-13 Shire Human Genetic Therapies Anticorps anti-flt-1 pour traiter la dystrophie musculaire de duchenne

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014117160A1 (en) * 2013-01-28 2014-07-31 Shire Human Genetic Therapies, Inc. Anti-flt-1 antibodies in treating duchenne muscular dystrophy

Also Published As

Publication number Publication date
JP2018518153A (ja) 2018-07-12
AU2016246722A1 (en) 2017-10-26
AU2022200466B2 (en) 2024-06-13
CA2981954A1 (en) 2016-10-13
CN114539408B (zh) 2025-03-11
US20180072806A1 (en) 2018-03-15
US20240076387A1 (en) 2024-03-07
MA41899A (fr) 2018-02-13
WO2016164528A1 (en) 2016-10-13
MX2017012828A (es) 2018-06-19
JP6993880B2 (ja) 2022-01-14
HK1249912A1 (en) 2018-11-16
BR112017021414A2 (pt) 2018-07-03
JP7741225B2 (ja) 2025-09-17
WO2016164528A9 (en) 2017-01-12
CN114539408A (zh) 2022-05-27
CN120290577A (zh) 2025-07-11
EP3280734B1 (en) 2022-01-26
US10787515B2 (en) 2020-09-29
PL3280734T3 (pl) 2022-07-04
ES2910783T3 (es) 2022-05-13
EP4056593A1 (en) 2022-09-14
CN107787330B (zh) 2022-02-01
US12435146B2 (en) 2025-10-07
US20210206860A1 (en) 2021-07-08
JP7456989B2 (ja) 2024-03-27
EP3280734A1 (en) 2018-02-14
AU2022200466A1 (en) 2022-02-17
CN107787330A (zh) 2018-03-09
JP2024069463A (ja) 2024-05-21
JP2022040124A (ja) 2022-03-10

Similar Documents

Publication Publication Date Title
AU2022200466B2 (en) Anti-Flt-1 antibodies for treating duchenne muscular dystrophy
US20210163603A1 (en) Anti-flt-1 antibodies in treating duchenne muscular dystrophy
JP7051150B2 (ja) 気分障害の治療及び診断のための抗－配列類似性１９を持つファミリー、メンバーａ５抗体の用途
TW200936608A (en) Improved anti-TrkB antibodies
BR122012004341A2 (pt) Anticorpos monoclonais contra proteína rgm a e usos destes
CA2944402A1 (en) Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
CA2981954C (en) Anti-flt-1 antibodies for treating duchenne muscular dystrophy
HK40079861A (en) Anti-flt-1 antibodies for treating duchenne muscular dystrophy
HK1249912B (en) Anti-flt-1 antibodies for treating duchenne muscular dystrophy
BR112017021414B1 (pt) Anticorpos anti-flt-1 e composição farmacêutica compreendendo os referidos anticorpos
BR122024023570A2 (pt) Polinucleotídeo que codifica um anticorpo anti-flt-1 ou seu fragmento de ligação ao antígeno, composição farmacêutica, usos relacionados, vetor de expressão, célula isolada e anticorpos anti-flt-1 ou seu fragmento de ligação ao antígeno
HK1217710B (en) Anti-flt-1 antibodies in treating duchenne muscular dystrophy

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER APPLICANT(S): SHIRE HUMAN GENETIC THERAPIES, INC.

FGA Letters patent sealed or granted (standard patent)